Vivimed Labs' Q3 FY 2025-26 Quarterly Results

Result Summary

• Vivimed Labs Ltd reported a 23.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 56.3%.
• Its expenses for the quarter were up by 15.7% QoQ and down 23.5% YoY.
• The net profit increased 126.7% QoQ and increased 176.8% YoY.
• The earnings per share (EPS) of Vivimed Labs Ltd declined at 1.94 during Q3 FY 2025-26.

Financial Statments for Q3 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vivimed Labs Ltd is a company engaged in the pharmaceutical and related industries. It primarily focuses on the production and distribution of pharmaceutical ingredients, specialty chemicals, and other healthcare-related products. The company has been known for its broad portfolio in the healthcare sector, offering a range of products that cater to various medical and cosmetic needs. Any recent major developments regarding the company are not specified in the data provided.

Revenue

During the third quarter of fiscal year 2026 (Q3FY26), Vivimed Labs Ltd reported a total income of ₹15.99 crores. This represents a decline of 23.2% from the previous quarter (Q2FY26), where the total income stood at ₹20.82 crores. When compared to the same quarter in the previous fiscal year (Q3FY25), which reported a total income of ₹36.58 crores, there is a significant year-over-year decrease of 56.3%. These figures highlight the changes in the company's revenue over the specified periods.

Profitability

In terms of profitability, Vivimed Labs Ltd experienced a substantial loss during Q3FY26, with a profit before tax (PBT) of -₹16.55 crores. This reflects a deeper loss compared to the previous quarter (Q2FY26), which recorded a PBT of -₹7.30 crores, indicating a quarter-over-quarter increase in losses by 126.7%. Compared to Q3FY25, where the PBT was -₹5.98 crores, the year-over-year increase in losses is 176.8%. The company's earnings per share (EPS) also show a similar trend, with a value of -₹1.94 in Q3FY26, worsening from -₹0.85 in Q2FY26 and -₹0.70 in Q3FY25.

Operating Metrics

Vivimed Labs Ltd's total expenses in Q3FY26 amounted to ₹32.54 crores, which is a 15.7% increase from the previous quarter's expenses of ₹28.13 crores. However, when compared to Q3FY25, which had total expenses of ₹42.55 crores, there is a year-over-year decrease of 23.5%. These figures highlight changes in the company's cost structure over the periods in question. As the company did not incur any tax expenses during these quarters, profit after tax figures mirror the profit before tax values, indicating a consistent approach in tax handling within the financial periods observed.